<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with systemic <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JRA</z:e>) are often poorly responsive to existing therapeutic modalities </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the effectiveness of pulse therapy consisting of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> 30 mg/kg/day for 3 consecutive days combined with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 0.4 g/m2 body surface area on the 3rd day, for 18 patients with definite systemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JRA</z:e>, who were enrolled in an open trial of 12 months' duration </plain></SENT>
<SENT sid="2" pm="."><plain>The children received pulse therapy every 3 months; oral <z:chebi fb="0" ids="44185">methotrexate</z:chebi> 10 mg/m2 was started after the first pulse </plain></SENT>
<SENT sid="3" pm="."><plain>A rapid and clinically significant suppression of systemic and articular manifestations was seen in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Significant decreases in laboratory indices of disease activity were also observed </plain></SENT>
<SENT sid="5" pm="."><plain>Side effects were minor and reversible </plain></SENT>
<SENT sid="6" pm="."><plain>The results of our preliminary trial support the development of a controlled study to evaluate the efficacy of pulse therapy in systemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JRA</z:e> </plain></SENT>
</text></document>